The moment a patient with advanced cancer signs a consent form, the law assumes a rational actor weighing risks and benefits with clear eyes. A new empirical study from Germany suggests that this assumption deserves far more scrutiny than it typically receives. Researchers led by Sabine Sommerlatte, Theresa Schneider and Jan Schildmann at the Institute of History and Ethics of Medicine at Martin Luther University Halle-Wittenberg found that many patients with advanced lung, oesophageal or liver cancer show measurable weaknesses in the understanding and reasoning components of decision-making capacity at exactly the point when they are asked to consent to treatment. The findings, published in the Journal of Cancer Research and Clinical Oncology, also reveal a striking statistical link between psychological distress and decisional conflict, suggesting that anxiety and depression may be quietly undermining the informed consent process in oncology wards.
The study addressed a long-standing tension in clinical ethics. Informed consent is the legal and moral cornerstone of modern medicine, resting on the premise that patients can comprehend relevant information, appreciate its application to their own situation, reason through treatment options and communicate a choice. Yet cancer diagnosis and its treatment are among the most psychologically taxing experiences a person can face. Clinicians have long suspected, and bioethicists have repeatedly argued, that emotional overload could compromise the very capacities that consent is meant to demonstrate. What has been missing, until now, is systematic empirical data collected from patients at the actual moment of consent, rather than in abstract ethical commentary.
To fill that gap, the research team conducted structured interviews with 56 patients diagnosed with advanced pulmonary, oesophageal or liver cancer. The interviews took place before the start of therapy, capturing participants in the clinically real and ethically critical window in which treatment decisions are actually made. Fifty-five percent of the participants were male, and the mean age was 61.14 years. Rather than relying on clinician impressions, the researchers deployed three validated psychometric instruments, each targeting a different dimension of the consent process.
The central instrument was the MacArthur Competence Assessment Tool for Treatment, or MacCAT-T, a semi-structured interview widely regarded as the gold standard for assessing decision-making capacity in clinical settings. The MacCAT-T breaks capacity into four operational domains: understanding, which measures whether a patient grasps the medically relevant facts; appreciation, which tests whether the patient recognizes those facts as applying to his or her own case; reasoning, which evaluates the ability to compare options and process consequences; and expressing a choice. Trained interviewers posed standardized questions about the patient’s specific treatment situation, and responses were scored against defined criteria, producing a quantitative profile of each patient’s capacity rather than a binary competent-or-not verdict.
The psychological dimension was captured with the Hospital Anxiety and Depression Scale, or HADS, a 14-item instrument designed specifically for medically ill populations. Its designers deliberately excluded somatic symptoms such as fatigue and insomnia that could be attributable to the disease itself, isolating the affective components of anxiety and depression. A score of seven or above on the anxiety subscale and five or above on the depression subscale is conventionally treated as clinically relevant. Decisional conflict, a construct describing the subjective uncertainty a patient feels when making a health decision, was measured with the Decisional Conflict Scale, or DCS, with scores above 37.5 indicating significant conflict likely to impair implementation of a decision.
The results were sobering on every front. On the MacCAT-T, patients showed comparatively low performance in the domains of understanding and reasoning, the two cognitive pillars of informed choice. Understanding requires patients to absorb and retain complex information about diagnosis, prognosis, therapeutic alternatives and side effects, often delivered under time pressure and in emotionally charged conversations. Reasoning demands that patients manipulate that information, weighing a burdensome therapy against its uncertain benefits. That these two domains, rather than appreciation or expression of choice, were the weak points is particularly concerning, because deficits in understanding and reasoning strike directly at the epistemic basis of consent.
The distress data were equally alarming. Among the 48 patients who completed the HADS, the mean score on the anxiety subscale was 7, exactly at the established clinical cut-off, while the mean depression score was 5.81, above its cut-off of 5. In other words, on average, this patient population was experiencing clinically relevant symptoms of both anxiety and depression before therapy had even begun. These are not marginal elevations in a handful of vulnerable individuals; they characterize the group as a whole, painting a picture of a patient collective carrying a substantial psychological burden into decisions about life-prolonging or life-altering treatment.
The link between distress and difficulty deciding emerged with impressive statistical clarity. Among the 45 patients who completed the DCS, 15, or 33.3 percent, exhibited significant decisional conflict at the threshold of 37.5. When the researchers examined the relationships between measures, they found strong positive correlations between psychological distress and decisional conflict: the Spearman correlation coefficient between the anxiety subscale and the DCS was 0.564, and between the depression subscale and the DCS it was 0.511, both highly significant at p < 0.001. In practical terms, the more anxious and depressed a patient was, the more torn, uninformed and unsupported that patient tended to feel in the decision itself. One in three patients, meanwhile, faced a decisional conflict severe enough that, by the scale’s own criteria, the resulting choice was at elevated risk of being poorly implemented or later regretted.
The authors are careful about what these correlations do and do not demonstrate. A cross-sectional design cannot establish whether distress causes decisional conflict, whether the struggle to decide amplifies distress, or whether a third factor, such as disease severity or poor physician-patient communication, drives both. What the data do establish, however, is a robust empirical association in exactly the population where informed consent matters most, and they lend quantitative weight to a concern that has mostly been argued on theoretical grounds. The ethical implications are considerable. If a substantial fraction of patients consent to therapy while their capacity to understand and reason is degraded and while a third are in significant decisional conflict, the procedural formality of a signature may be masking a substantively compromised consent.
The researchers themselves draw a practical conclusion from their findings. Because the deficits cluster in understanding and reasoning, the appropriate response is not to strip patients of their decisional authority but to support it. Psychological support and structured guidance in decision-making, the authors conclude, may improve patients’ ability to make informed choices. Structured decision aids, teach-back techniques in which patients restate the information in their own words, staged consent conversations spread over multiple encounters, and routine screening for anxiety and depression before major treatment decisions are all concrete interventions that follow logically from the data. The study also underscores the value of formal capacity assessment tools like the MacCAT-T in oncology practice, since clinician judgment alone frequently fails to detect subtle capacity impairments.
The study’s design carries both strengths and limitations worth noting. Its strength lies in grounding an abstract ethical debate in psychometric data gathered from real patients at the real moment of consent, across three different advanced cancer types and multiple German clinical centers, including partners at Heidelberg University Hospital, Ruhr University Bochum’s St. Josef Hospital, the Hemer lung clinic and the Technical University of Munich. Its limitations include the modest sample size of 56 patients, the restriction to three tumor entities, and the absence of longitudinal follow-up to track how capacity and conflict evolve during treatment. The authors also acknowledge that the MacCAT-T measures performance on a given day rather than underlying competence, meaning that transient distress during the interview itself could depress scores.
Funded by a grant from German Cancer Aid, the study arrives at a time when oncology is grappling with increasingly complex treatment landscapes, from multimodal regimens to molecularly targeted therapies whose risk-benefit profiles are difficult even for specialists to communicate clearly. As choices multiply, the cognitive and emotional load placed on patients at the consent moment only grows. This study provides some of the clearest empirical evidence yet that the load may be more than many patients can carry unaided, and that protecting autonomy in advanced cancer may require treating the mind’s distress as seriously as the body’s disease. The signature on the consent form, the researchers suggest, is only as informed as the psychological state of the hand that signs it.
Subject of Research: Decision-making capacity, psychological distress and decisional conflict in patients with advanced lung, oesophageal or liver cancer at the time of treatment consent
Subject of Research: Cancer
Article Title: Decision-making capacity, distress and decisional conflicts of patients with advanced cancer at the time of consent: empirical findings and ethical implications
Article References: Sommerlatte, S., Schneider, T., Haberstroh, J., Heise, C., Lambrecht, N., Michl, P., Porzelle, J., Rauschenberg, S., Reinacher-Schick, A., Richter, M., Roick, J., Rosenau, H., Schulmann, K., & Schildmann, J. (2026). Decision-making capacity, distress and decisional conflicts of patients with advanced cancer at the time of consent: empirical findings and ethical implications. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06585-8
Image Credits: AI Generated
DOI: 10.1007/s00432-026-06585-8
Keywords: decision-making capacity, decisional capacity, competence to consent, informed decision-making, decisional conflict, advanced cancer, MacCAT-T, psychological distress, HADS, oncology ethics
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 11, 2026). Advanced cancer patients face distress and conflict when consenting to treatment. Scienmag. https://scienmag.com/advanced-cancer-patients-face-distress-and-conflict-when-consenting-to-treatment/
Nathaniel Bowman. “Advanced cancer patients face distress and conflict when consenting to treatment.” Scienmag, 11 September 2026, https://scienmag.com/advanced-cancer-patients-face-distress-and-conflict-when-consenting-to-treatment/. Accessed 11 September 2026.
Nathaniel Bowman. “Advanced cancer patients face distress and conflict when consenting to treatment.” Scienmag. September 11, 2026. https://scienmag.com/advanced-cancer-patients-face-distress-and-conflict-when-consenting-to-treatment/
Copy citation Download RIS
Tags: advanced cancer patient decision-making capacitydecision-making capacity in oncology patientsdecisional conflict among advanced cancer patientsdecisional conflict in oncologyemotional factors affecting informed consentempirical research on cancer patients’ understanding and reasoningempirical study on cancer patient consentethical challenges in cancer treatment consentethical challenges in cancer treatment consent processimpact of anxiety and depression on cancer treatment decisionsimpact of anxiety and depression on medical decision-makingimplications for clinical ethics and patient autonomyInformed consent in advanced cancer treatmentlegal and moral aspects of cancer treatment decisionslegal and moral considerations of informed consent in oncologymental health and medical ethicsmental health effects on cancer treatment decision-makingpatient autonomy in advanced cancerpatient understanding and reasoning in cancer carepsychological distress and informed consent in oncologypsychological distress and treatment decisionsstudy of patient comprehension and reasoning in cancer care
